GlaxoSmithKline

Showing 15 posts of 164 posts found.

GSK takes £2.2bn hit from Avandia claims

January 18, 2011
Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone

GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …

GSK moves Crohn’s disease drug into phase III

January 14, 2011
Research and Development ChemoCentryx, Crohn’s disease, GSK’786, GlaxoSmithKline, Traficet-EN

GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …

Anti-cancer stem cell drug starts clinical trials

January 14, 2011
Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers

OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …

GSK's UK headquarters

End of the line for GSK’s resveratrol

January 14, 2011
Research and Development GSK, GlaxoSmithKline, SRT2104, SRT2379, SRT501, Sirtris, multiple myeloma, resveratrol

GlaxoSmithKline is halting all work on resveratrol, a compound found in red wine and thought to have life extending properties. …

GlaxoSmithKline’s H1N1 vaccine Pandemrix

Doctors use GSK’s Pandemrix as seasonal flu vaccines fall short

January 10, 2011
Sales and Marketing GSK, GlaxoSmithKline, Pandemrix, flu, h1n1, influenza, vaccines

Doctors may have to use last year’s stock of the H1N1 vaccine Pandemrix as the government admits there are some …

GSK's UK headquarters

GSK signs £64m autoimmune antibody deal

January 7, 2011
Research and Development GSK, GlaxoSmithKline, ImmuTune IMP731, Immutep, autoimmune diseases

GlaxoSmithKline has signed a worldwide licence agreement for a novel antibody designed to treat autoimmune diseases.The company will pay up …

GSK's UK headquarters

GSK hits back at 60 Minutes whistleblower interview

January 6, 2011
Manufacturing and Production 60 Minutes, Avandamet, Bactroban, Cheryl Eckard, GSK, GlaxoSmithKline, Kytril, Paxil, manufacturing compliance

GlaxoSmithKline has responded to an edition of US current affairs show 60 Minutes centring on manufacturing problems at its now-closed …

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

GSK buys sports nutrition company for £162m

December 14, 2010
Sales and Marketing GSK, GlaxoSmithKline, Maximuscle, Maxinutrition, consumer healthcare, sports nutrition

GlaxoSmithKline has acquired UK sports nutrition firm Maxinutrition for £162 million to help broaden its consumer portfolio. The company already …

GSK acquires China’s Nanjing MeiRui Pharma for $70m

December 8, 2010
Manufacturing and Production, Sales and Marketing China, GSK, GlaxoSmithKline, Nanjing MeiRui Pharma, Pagoda Pharmaceuticals, SheNiTing

GlaxoSmithKline has continued its expansion into China with the $70 million acquisition of a local firm. Nanjing MeiRui Pharma Co’s …

GSK's UK headquarters

UK tax reforms prompt £500m manufacturing investment by GSK

November 30, 2010
Manufacturing and Production GSK, GlaxoSmithKline, UK corporation tax, patent box, pharma manufacturing

A decision by the UK Government to reform the corporation tax system has been followed by a major job creation …

GlaxoSmithKline forges Russian vaccines alliance

November 30, 2010
Manufacturing and Production GSK, GlaxoSmithKline, JSC Binnopharm, cervical cancer vaccine, pharma manufacturing, pneumococcal vaccine, rotavirus vaccine, vaccines

GlaxoSmithKline has announced an alliance with JSC Binnopharm focusing on the secondary manufacture of a number of the pharmaceutical giant’s …

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

GSK partners with Brazil’s Fiocruz on tropical disease research

November 15, 2010
Research and Development Chagas disease, Fiocruz, GSK, GSK’s Tres Cantos Medicines Development Campus, GlaxoSmithKline, Oswald Cruz Foundation, leishmaniasis

GlaxoSmithKline and the Brazil-based Oswald Cruz Foundation (Fiocruz) are to research and develop new medicines for tropical diseases Chagas and …

GSK signs rare diseases deal with Amicus

November 1, 2010
Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …

The Gateway to Local Adoption Series

Latest content